On Thursday, Shares of Amgen, Inc. (NASDAQ:AMGN), gained 1.48% to $152.31.
The Amgen Foundation, declared that it will invest more than $4 million to support and strengthen the Amgen Biotech Experience program across the United States, Puerto Rico, United Kingdom and Ireland. The Amgen Biotech Experience comprises an engaging series of labs that effectively bring biotechnology into classrooms. This new commitment will also strengthen the program’s alignment with the United States’ Next Generation Science Standards, which are focused on engaging students in more authentic science learning experiences. With the support of Education Development Center, Inc. (EDC), the global nonprofit leading the Amgen Biotech Experience Program Office, the investment is predictable to empower 1,000 teachers who will reach more than 150,000 new students with the labs over the next two years.
“We are very excited to extend our commitment to the Amgen Biotech Experience, a program that began 25 years ago, with the intent to ignite a deep passion for innovation and scientific discovery in students,” said Robert A. Bradway, chairman and chief executive officer of Amgen. “This program, which provides advanced biotech curriculum and professional-grade lab equipment at no cost to schools, has opened countless students’ eyes to the world of biotechnology, fueling potential long term advancements to both medicine and society.”
The Amgen Biotech Experience labs were designed by Amgen scientists and educators to inspire the next generation of innovators and give high school biology students the opportunity to experience real science at their fingertips. The Amgen Biotech Experience does this by providing science teachers with advanced training, curriculum and research-grade equipment, allowing them to run labs in their classrooms that incorporate the core technologies used by the biotech industry in the discovery of human therapeutics. With the assist of secondary school teachers inside and outside the United States, 72,000 students across Amgen regions take partd in the labs this past year.
Amgen Inc., a biotechnology company, discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses for the treatment of illness in the areas of oncology, hematology, inflammation, bone health, nephrology, cardiovascular, and general medicine.
Shares of Mastercard Inc (NYSE:MA), inclined 1.47% to $98.02, during its last trading session.
MasterPass has increasingly been making shopping easier and safer for consumers and merchants in 24 countries around the globe. MasterCard declared it will integrate a fully tokenized checkout experience within MasterPass, leveraging the MasterCard Digital Enablement Service (MDES). This gives consumers the freedom to shop more securely online or in-app from any connected device. A demonstration of a tokenized MasterPass wallet will be available next week at the Money 20/20 Conference in Las Vegas.
MasterPass enables issuers to deliver digital payments across channels and devices around the world, seamlessly extending the trusted relationships consumers have with their banks. It securely stores shoppers’ preferred payment and shipping information, which makes checkout just a few clicks away, with no long strings of numbers or details to enter. The “Buy with MasterPass” button is presently found within the website and apps of more than 250,000 merchants globally across travel, entertainment, quick service restaurants, retail and more.
At the request of Issuers enabling MasterPass for their customers, MasterCard will replace the personal account numbers (PAN) for consumer credit, debit, commercial and prepaid cards stored in MasterPass with a secure “token” – a new 16-digit number that represents the existing PAN on the front of a payment card. Tokens are unique to each bank-connected MasterPass wallet and carry EMV-based security protection that provides additional peace of mind for consumers and merchants alike.
MasterCard Incorporated, a technology company, provides transaction processing and other payment-related products and services in the United States and internationally. The company facilitates the processing of payment transactions, counting authorization, clearing, and settlement, in addition to delivers related products and services.
Finally, Shares of Humana Inc (NYSE:HUM), ended its last trade with -6.80% loss, and closed at $165.11.
The era of getting a prescription from your doctor, only to learn later that the medication is not covered, is coming to an end. Health and wellness company Humana Inc. (HUM) has declared a real-time prescription drug benefit service that gives doctors information about their Humana patients’ drug coverage, pricing and network pharmacy options all while the patient is in the exam room.
Delivered to physicians through DrFirst’s myBenefitCheck, the IntelligentRx service provides doctors with patient-specific prescription price information at the time the prescription is being written. The service is predictable to reduce the impact of cost on medication access and adherence by assisting doctors and patients consider medication cost as part of their drug therapy regimen.
Humana Pharmacy president William Fleming says assisting doctors make more informed prescribing decisions is key to medication access and adherence, and therefore critical to improving clinical outcomes.
Humana Inc., together with its auxiliaries, operates as a health and well-being company. The company operates through three segments: Retail, Group, and Healthcare Services. The Retail segment provides Medicare and commercial fully-insured medical and specialty health insurance benefits, counting dental, vision, and other supplemental health and financial protection products directly to individuals.